Nirman Share Brokers - Biocon Share Price

By Author: NIRMAN
Total Articles: 17
Comment this article

BIOCON SHARE PRICE

In 2014, Biocon launched canmab (trastuzumab), a treatment for breast cancer, in India. Biocon Cell was launched in the same year as a resulting partnership between Biocon and ISB Innovation Management.

In the 1990s, Biocon Biochemicals Limited expanded its own research program and introduced new technologies. It was acquired by Unilever PLC and merged with Unilever's subsidiary Quest International. Axicorp GmbH, the German subsidiary of Biocon, was sold to Biocon in 2011, with Biocon acting as promoter and shareholder.

In 1993 the research and development facilities of Biocon Biochemicals Limited in Germany were certified according to ISO 9001: RWTVU. Biocon Ltd. is a holding company engaged in the manufacture, research and development of therapeutics. The company was founded in 1994 as Biocon Biosciences Limited as a bespoke research company to meet the growing need for outsourced research and development in the pharmaceutical sector.

Biocon Limited is a large integrated innovation and leading biopharmaceutical company. It has a rich pipeline of biosimilars ...
... and new biologics at different stages of development, including insulin and Tregopil, an oral insulin with a high potential. Biocon is a first-class pharmaceutical brand that enriches the pharmaceutical industry through its commitment.

For orientation purposes, we have compiled all the relevant data on the share price, the share price and the historical price. Biocon, Asia's largest biotechnology company, started out with INR 10,000 in 1978 and is now a billion-dollar company. Flagship companies of Reliance Industries Limited, Fortune Global 500 Company and India’s largest private sector company are Flagship companies of Reliance Industries Limited and Fortune Global 500 Company.

In 2011, Biocon announced the planned commissioning of the first world-class biopharmaceutical production and research facility, Bio-Xcell, in Malaysia. BioCon launched Insupen in 2011, a practical and affordable reusable insulin delivery system, and in 2012 the company released positive results of its phase 3 global study of recombinant human insulin.

In 2014, Silver Leaf Oak Mauritius Limited, an investment vehicle advised by India Value Fund Advisors, agreed to acquire a 10% minority interest in Syngene International Limited, Biocons''s "research and services subsidiary". Silver Leaf acquired a stake in Biocon Research Limited, a wholly owned subsidiary of Biocon Limited, for 3,800 rupees. Biocon Ltd (ICICI Securities Limited) was aiming for $37,740 ($41,000), at $26.8 and $11.63, respectively, and the holding broker reported that Biocon had entered into a strategic alliance with SIL to offer Biocon a 15% stake and a cash valuation for the company of $4.9 billion.

The strategic alliance with SILs grants Biocon Ltd. and ICICI Securities limited access to 100 million vaccine doses per year and marketing rights, including COVID-19 vaccines for the global markets for 15 years, and also developed antibody service level agreements (SLAs) for manufacture and distribution of vaccines and antibodies. As the company is trading with a high valuation, it is recommended to keep it at a TP of 400 rupees.

As of June 2021, the promoters will own 60.64% of the shares in Biocon, with the shares pledged. In 1999, she explained the history of Glentec International said that her husband was fond of the company as an investment company with its foreign exchange income to buy shares in Unilever, which it held before becoming a public company, and various other investments in real estate on the public market. The company has invested $55 million in the property including four properties in London, one in Barcelona and one in New York as well as an upscale home worth $30 million.

SEBI and regulators do not know whether Kunal Kashyap is the protector of Deanstone Trust which was established in July 2015 in New Zealand by a Mauritius-based Glentec International settler. The trust is part of a complex set of records being investigated by The Indian Express.

Please note that LKP Wealth Advisory Ltd does not guarantee or warrant any return or profit to its customers or subscribers. Our customers and third parties have no right to participate in our recommendations or other information provided by us or received by our customers or third parties.

Investment advice is the personal view of the research team. Fusion Media accepts no responsibility for any trading losses that you may incur as a result of your use of information. Share price targets and forecasts apply in the short, medium and long term.

The price-earnings ratio is the value of a company as measured by the current share price in relation to earnings per share. Earnings per share is a company's share of net income attributable to shares outstanding. It is calculated after deducting the preference shares divided by the net profit of the company, which is then divided by the number of shares outstanding (i.e.
The Biocon share price includes details of the Biocon share price, live share price, daily highs and lows, 6-month and 1-year returns and more. Find out how Biocon's current share price has evolved and how it can help you analyze the company's current and historical prices. It includes Biocon's share price chart, description of historical performance, financial statements and much more.

Sensex, BSE Quotes, Nifty and NSE Quotes are real-time quotes and licensed by BSE & NSE. KYC is a one-off transaction in the securities markets and is managed through SEBI registered intermediaries such as DP Mutual Funds.

GrowW is an investment platform where users can find the best investment funds to invest their money in without any hassle. GrowW provides an objective assessment of investment funds and does not advise or recommend a portfolio of investment funds. If you want to manage your personal finances and invest well, you can find the OnStock Exchange here.